Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Differentiating the Effects of Substance P and Beta-endorphin in the Perception of Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In previous studies we demonstrated that endogenous opioids (inhibitory neuropeptides)
modulate the perception of breathing difficulty in patients with chronic obstructive
pulmonary disease (COPD). Recently, we found that antagonism of substance P (an excitatory
neuropeptide) with aprepitant did not affect the perception of breathing difficulty. However,
after administration of aprepitant, blood levels of both substance P(+ 54 ± 39%) and
beta-endorphin (+ 27 ± 17%) increased significantly. As these blood levels reflect
cellular/tissue activity, we postulated that the concomitant release of excitatory (substance
P) and inhibitory (beta-endorphin) neuropeptides had opposing effects (counterbalanced each
other) on the perception of breathing difficulty.
The objective of the present study is to further examine the possible role of substance P on
the perception of breathlessness. We propose to administer oral aprepitant and oral placebo
in a randomized clinical trial in patients with COPD. However, four hours after patients take
these medications, intravenous naloxone will be administered in order to block the effects of
endogenous opioids (beta-endorphin) on opioid receptors. Five minutes later, patients will
breathe thru a tube with fine wire mesh to provoke breathing difficulty, and then provide
ratings of the intensity and unpleasantness of breathlessness every minute.
The two competing hypothesis of the study are:
1. if breathlessness ratings with aprepitant/naloxone = placebo/naloxone, then substance P
has no effect on perception of breathing difficulty;
2. if breathlessness ratings with aprepitant/naloxone ≠ placebo/naloxone, then substance P
has an effect on perception of breathing difficulty.
This study is a randomized, controlled clinical trial comparing the acute effects of oral
aprepitant (selective antagonist of substance P receptor) vs. placebo on ratings of
breathlessness during resistive load breathing in patients with COPD. Four hours after
randomization, all patients will receive intravenous naloxone (antagonist of opioid
receptors) to block the effects of endogenous opioids on perception of breathlessness. The
two competing hypothesis of the study are:
Breathing difficulty will be induced by the patient breathing thru a tube with fine wire mesh
for approximately 10 - 20 minutes in the laboratory.
Approximately 20 patients with COPD will be recruited from the out-patient clinic at the
Dartmouth-Hitchcock Medical Center. The population will consist of female or male adults at
least 50 years of age, at least 10 pack-year history of smoking, and a diagnosis of COPD
associated with chronic bronchitis based on standard criteria.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|